BGT.AU Bio-Gene Technology Ltd
- Market cap
- AUD 6.13M
- P/E
- -
- P/B
- 2.93x
- ROE
- -111.5%
- Dividend yield
- -
- Fundamental score
- 0.9/5
Ratios use the latest price and the fiscal year ending Jun 2026.
Is BGT.AU undervalued?
Graham numberThe Graham number of Bio-Gene Technology Ltd cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Bio-Gene Technology Ltd fundamental analysis
5 of 21 checks passedROE 0/2
Low return on equity (-111.5%), below 10%.
ROA 0/1
Return on assets (-89.3%) is below the industry median (-35.4%).
Profit Consistency 0/2
Not profitable for at least 3 consecutive years.
Earnings Growth 5Y 1/1
Earnings per share grew over the past 5 years.
Earnings Acceleration 0/1
Not enough positive earnings history to compare last year's growth with the 5-year average.
Earnings Growth vs Industry 1/1
Last year's EPS growth (38.4%) is above the industry median (-12.5%).
Revenue Growth 0/2
Revenue did not grow over the past 3 years or is not reported.
Short-term Liquidity 1/1
Current assets cover short-term liabilities.
Long-term Liabilities 1/1
Current assets cover long-term liabilities.
Debt to Equity 0/2
Debt to equity cannot be calculated: debt is not reported or equity is negative.
Debt Trend 0/1
Debt to equity has risen over the past 5 years.
Cash Runway 1/2
Cash covers 1.0 years of the current cash burn.
PE vs Market 0/1
PE is negative or not available.
PE vs Industry 0/1
PE is negative or not available.
PBV 0/1
Price to book (2.9x) is above the industry median (2.2x).
Graham Number 0/1
Graham number needs positive earnings and book value.
PEG 0/1
PEG needs positive PE and positive 5-year earnings growth.
Dividend Yield 0/2
No dividend paid in the last reported year.
Dividend Stability 0/2
Dividends were not paid steadily for the past 5 years.
Dividend Growth 0/1
Dividends paid did not grow over the past 5 years.
Payout Ratio 0/1
No dividend, or no profit to pay it from.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
Bio-Gene Technology Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Bio-Gene Technology Ltd
Bio-Gene Technology Limited, an agtech development company, engages in the development and commercialization of naturally derived insecticide products in Australia and internationally. Its products include Flavocide, a synthetically produced nature-identical compound; and Qcide, a natural plant-derived oil with high levels of tasmanone. The company has a research collaboration agreement with James Cook University for experiments demonstrating the value of pre-conditioning bi…
Full company profileBio-Gene Technology Ltd financial statements
Bio-Gene Technology Ltd annual financial statements (AUD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 6.32K | 344K | 509K | 908K | 62.6K | 446K | 149K | 18.3K | 425K | - |
| Gross Profit | -437K | 246K | 402K | 640K | -111K | 179K | -164K | -301K | -246K | -42.0K |
| Operating Income | -1.16M | -3.30M | -2.19M | -2.16M | -2.60M | -3.41M | -3.63M | -3.06M | -3.07M | -3.41M |
| EBITDA | -1.12M | -3.13M | -2.15M | -2.10M | -2.85M | -2.92M | -3.14M | -2.97M | -2.58M | -3.36M |
| Net Income | -1.05M | -2.83M | -1.92M | -1.93M | -2.40M | -2.91M | -3.10M | -2.41M | -2.58M | -2.33M |
| EPS | -0.01 | -0.02 | -0.02 | -0.02 | -0.02 | -0.02 | -0.02 | -0.01 | -0.01 | -0.01 |
| Balance Sheet | ||||||||||
| Total Assets | 9.45M | 7.67M | 5.56M | 6.57M | 5.00M | 7.30M | 3.84M | 3.16M | 2.15M | 2.61M |
| Total Liabilities | 374K | 760K | 614K | 567K | 755K | 1.03M | 614K | 368K | 523K | 520K |
| Shareholders' Equity | 9.07M | 6.91M | 4.95M | 6.00M | 4.25M | 6.27M | 3.22M | 2.79M | 1.63M | 2.09M |
| Cash & Short-term Investments | 8.79M | 6.71M | 4.50M | 5.52M | 3.93M | 6.34M | 2.99M | 2.21M | 1.14M | 1.94M |
| Total Debt | 150K | - | 150K | 162K | 150K | - | - | - | 51.2K | - |
| Cash Flow | ||||||||||
| Operating Cash Flow | -729K | -2.37M | -2.20M | -1.64M | -1.83M | 43.5K | -3.28M | -2.75M | -2.54M | -1.94M |
| Capital Expenditure | 4.99K | 239K | 2.68K | 3.03K | 3.03K | 6.84K | 0.00 | 5.70K | 0.00 | 1.94M |
| Free Cash Flow | -734K | -2.61M | -2.20M | -1.64M | -1.83M | 36.7K | -3.28M | -2.76M | -2.54M | -1.94M |
| Ratios | ||||||||||
| ROE | -11.6% | -41.0% | -38.8% | -32.2% | -56.4% | -46.5% | -96.1% | -86.3% | -158.8% | -111.5% |
| ROA | -11.2% | -37.0% | -34.5% | -29.4% | -47.9% | -39.9% | -80.7% | -76.2% | -120.2% | -89.3% |
| Net Profit Margin | -16,702.1% | -822.5% | -377.3% | -213.0% | -3,827.3% | -653.8% | -2,074.5% | -13,150.5% | -608.0% | - |
| Debt to Equity | 0.02x | - | 0.03x | 0.03x | 0.04x | - | - | - | 0.03x | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Bio-Gene Technology Ltd dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2026 | - | - | - |
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | AUD 75.0K | 0.00 | - |
| 2021 | AUD 11.7K | 0.00 | - |
| 2020 | AUD 13.8K | 0.00 | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Bio-Gene Technology Ltd
- Insiders 44.74%
- Institutions 0.00%
- Public & others 55.26%
- Shares outstanding 438M
- Free float 242M
Bio-Gene Technology Ltd company profile
- Company name
- Bio-Gene Technology Ltd
- Ticker
- BGT.AU
- ISIN
- AU000000BGT8
- Exchange
- Australian Securities Exchange
- Sector
- Healthcare
- Industry
- Chemicals
- Fiscal year end
- June
- Address
- 400 Collins Street, Melbourne, VIC, Australia, 3000
- Phone
- 61 3 9068 1062
- Website
- bio-gene.com.au
About Bio-Gene Technology Ltd
Bio-Gene Technology Limited, an agtech development company, engages in the development and commercialization of naturally derived insecticide products in Australia and internationally. Its products include Flavocide, a synthetically produced nature-identical compound; and Qcide, a natural plant-derived oil with high levels of tasmanone. The company has a research collaboration agreement with James Cook University for experiments demonstrating the value of pre-conditioning biomass prior to distillation; Cesar for assessing the insecticidal activity of its molecules against a range of insect species; Advanced Molecular Technologies; CSIRO for a chemistry development process; the Department of Agriculture and Fisheries, Queensland Government for assessing activity against grain storage pests; Eurofins; Grain Research Development Corporation; Pacific Discovery Services; Purdue University; Southern Cross University for chemical analysis of natural products; University of Florida; and University of Technology. It serves animal health, crop protection, grain storage, public health, and consumer applications. The company was incorporated in 1995 and is based in Melbourne, Australia.
Bio-Gene Technology Ltd management
3- Mr. Timothy Owen Grogan B.Sc., LLBMD, CEO & Director
- Mr. Drew Speedy AGIA, B.Bus, CPACFO & Company Secretary
- Mr. Peter Donald May AFA1M, AFAIM, GAICD, M.B.A.Executive Director of Research & Development and Executive Director